17 December 2025   Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds.   Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l

17 October 2025   Hesperos Inc. has been awarded  a Phase IIB SBIR grant from the National Institute on Aging to investigate the effects of medication on cognitive impairment.   In humans, drug-induced cognitive decline may arise from subtle network‑level disruption, synaptic dysfunction, neurotransmitter imbalance and moderate neuroinflammation. However, these effects are very challenging to detect using standard in vitro models and animal testing. Cognitive decline is typic

30 June 2025   The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP), Sanofi reports . Riliprubart also holds this designation for CIDP in the EU and US.   By engineering its human-relevant CIDP-on-chip as preclinical tool for disease modelling and drug efficacy testing, Hesperos has played an instrumental role in achieving this outcome.   CIDP is an inflamma